Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as triazolam liquid oral drops
triazolam liquid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| triazolam liquid oral drops | EXPERIMENTAL | - |
| triazolam tablets | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| triazolam liquid oral drops | DRUG | 0.25 mg single dose oral drops |
| triazolam tablets | DRUG | 0.25 mg single oral dose |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG ...
Triazolam liquid is an oral drops formulation of triazolam, a small molecule drug developed by Pfizer, Inc. It is being studied as a liquid dosage form rather than a tablet. The program is in Phase 1 clinical development, and the specific medical conditions it is intended to treat have not been disclosed.
Triazolam liquid targets GABA-A receptor subunits, specifically GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It acts as a positive allosteric modulator at these receptors. This target profile is consistent with the benzodiazepine class of small molecule compounds.
Triazolam liquid is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor behind the clinical program for this oral drops formulation of triazolam.
Triazolam liquid is in Phase 1 clinical development. It is an investigational formulation and has not been approved by the FDA. The program has completed one Phase 1 trial to date, and there are currently no active trials listed for this asset.
Triazolam liquid has been studied in one completed Phase 1 trial, NCT01421043, titled a study to determine whether an oral drops formulation of triazolam is bioequivalent to a tablet formulation in healthy subjects. The trial enrolled 34 healthy volunteers in Belgium, was randomized, and used an active-controlled design.
Yes, triazolam liquid and triazolam liquid oral drops refer to the same asset. The oral drops description reflects the liquid dosage form being developed. Both names point to the same Pfizer Phase 1 program evaluating a drops formulation of triazolam.